Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death

Cancers illustrating resistance towards apoptosis is one of the main factors causing clinical failure of conventional chemotherapy. Innovative therapeutic methods which can overcome the non-apoptotic phenotype are needed. The AMP-activated protein kinase (AMPK) is the central regulator of cellular e...

Descripción completa

Detalles Bibliográficos
Autores principales: Law, Betty Yuen Kwan, Gordillo-Martínez, Flora, Qu, Yuan Qing, Zhang, Ni, Xu, Su Wei, Coghi, Paolo Saul, Fai Mok, Simon Wing, Guo, Jianru, Zhang, Wei, Leung, Elaine Lai Han, Fan, Xing Xing, Wu, An Guo, Chan, Wai Kit, Yao, Xiao Jun, Wang, Jing Rong, Liu, Liang, Wong, Vincent Kam Wai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444727/
https://www.ncbi.nlm.nih.gov/pubmed/28404910
http://dx.doi.org/10.18632/oncotarget.15616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444727/
https://www.ncbi.nlm.nih.gov/pubmed/28404910
http://dx.doi.org/10.18632/oncotarget.15616

Ejemplares similares